Heberprot-P is a Cuban medicine for the treatment of diabetic foot ulcers and this medicine is available in more than ten countries. Currently, this medicine is not available legally in the United States, but it is under testing process.
South Korean scientists have developed a transparent skin patch that tests glucose levels in perspiration (instead of blood) and simultaneously injects drugs through microneedles. Sensors in the patch can send the data collected from perspiration to Smartphone App. A need of medication will be checked by App and instruct microneedles in the patch to deliver drugs. Trials on mice and a couple of humans were successful and more tests are going to be conducted under challenging conditions. If the prototype is successful, then the patch could be available within a few years. It is expected that the cost of the patch is the same as the conventional diagnostics and treatment kit.
Dr. Melissa Schilling, Professor at the NYU Stern School of Business have found a connection between diabetes and Alzheimer's disease. She has found hyperinsulinemia is responsible for almost half of Alzheimer's cases. Hyperinsulinemia is a condition where excess levels of insulin are being circulated in the body. Her finding was published in the Journal of Alzheimer's Disease.
Researchers analyzed 2,525 participants, aged between 40 and 69 years for four-and-a-half years. They found that depression combined with the risk of developing diabetes will have an enhanced risk of developing type 2 diabetes. Results published in the journal Molecular Psychiatry.
The Salk scientists have announced a cure to diabetes. The scientists have found the ERR-gamma protein switch (which make lab-grown cells) more responsive to glucose and make them release insulin at a normal rate. Scientists have checked the new technology on mice models with type 1 diabetes (T1D) by transplanting mature lab-grown beta cells with the ERR gamma protein switch on. Half of the mice models with diabetes were found to be with the normal glucose levels within two months. If this technology is successful, one day, it is possible to grow insulin-producing beta cells from pluripotent stem cells taken from the patients. This technology is a more practical, applicable and affordable to all people. This research was published in the journal Cell Metabolism.
Researchers examined patients with liver disease for over ten years. The study shows that people with type 2 diabetes (T2D) may have a greater liver risk (3 times more) compared with those without type 2 diabetes. The reason for the liver disease in patients with type 2 diabetes is due to the buildup of fat within the liver cells. The buildup of fat within the liver cells is called non-alcoholic fatty liver disease (NAFLD). People can avoid NAFLD by following a proper diet. The team involves researchers from universities of Southampton and Edinburgh.
The National Center for Global Health and Medicine, Tokyo, hopes to transplant insulin-producing pig cells into humans to cure type 1 diabetes (T1D) as the Japan government relaxed rules. They want to do this within three years.
Mississippi is the most obese citizen's state in the United States. As obesity of the citizens is high, diabetes health care costs ($10,507, 4Th highest) and premature deaths (487 per 10,000) are also high. Incidentally, nine of the ten most obese states are in the south.
The Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by the surgeon or physician or doctor. Published article is not a medical advice by the OWNER of the "Diabetes News Chronicle" website or by the AUTHOR of the article.
Published by Jammi Vasista, Chennai, India.